Aurinia Pharmaceuticals Inc. provided earning guidance for 2022. For fiscal year 2022, the Company maintains its net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150 to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.02 USD | 0.00% | -2.71% | -44.16% |
May. 07 | Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value | CI |
May. 02 | Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.16% | 716M | |
+5.66% | 111B | |
+11.23% | 105B | |
-0.38% | 21.93B | |
-12.15% | 22.34B | |
-7.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Earning Guidance for 2022